In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuronetics Inc.

www.neurostar.com

Latest From Neuronetics Inc.

Medtech Business Models: All Razor And No Blades – Is “Big Iron” Back In Vogue?

The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.

Market Intelligence Business Strategies

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Financing StartUps and SMEs

Nexstim Looks To Break Into US TMS Market With Depression Indication

The Helsinki-based company had expected stroke rehabilitation to be the first FDA-cleared indication for its Navigated Brain Therapy system, but while more data is collected for that program, it is pursuing a 510(k) clearance for NBS to treat major depressive disorder and plans to build a US salesforce to market NBS for therapeutic indications.

Clinical Trials Innovation

Neuronetics Launches Major Registry To Track NeuroStar TMS Outcomes

The registry will collect data from more than 6,000 depression patients treated with transcranial magnetic stimulation at more than 100 different treatment facilities in the US to better understand how the therapy benefits patients in the "real world."

Research & Development Innovation
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neuronetics Inc.
  • Senior Management
  • Christopher Thatcher, Pres. & CEO
    Peter Donato, CFO
    Greg Harper, VP, Product Dev. & Operations
    Cassie Hallberg, VP, Mktg.
    Steve MacKinnon, VP, Sales
  • Contact Info
  • Neuronetics Inc.
    Phone: (877) 600-7555
    3222 Phoenixville Pike
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register